MA46762A - Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnm - Google Patents
Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnmInfo
- Publication number
- MA46762A MA46762A MA046762A MA46762A MA46762A MA 46762 A MA46762 A MA 46762A MA 046762 A MA046762 A MA 046762A MA 46762 A MA46762 A MA 46762A MA 46762 A MA46762 A MA 46762A
- Authority
- MA
- Morocco
- Prior art keywords
- rna
- improved process
- lipid nanoparticles
- nanoparticles loaded
- preparing lipid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/53—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
- C12Y114/16001—Phenylalanine 4-monooxygenase (1.14.16.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/03—Carboxy- and carbamoyltransferases (2.1.3)
- C12Y201/03003—Ornithine carbamoyltransferase (2.1.3.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
- C12Y603/04005—Argininosuccinate synthase (6.3.4.5)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662420413P | 2016-11-10 | 2016-11-10 | |
| US201762580155P | 2017-11-01 | 2017-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46762A true MA46762A (fr) | 2019-09-18 |
Family
ID=60782328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046762A MA46762A (fr) | 2016-11-10 | 2017-11-10 | Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnm |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20180153822A1 (fr) |
| EP (1) | EP3538073A1 (fr) |
| JP (2) | JP7738979B2 (fr) |
| AU (1) | AU2017357758B2 (fr) |
| CA (1) | CA3041345A1 (fr) |
| MA (1) | MA46762A (fr) |
| WO (1) | WO2018089801A1 (fr) |
Families Citing this family (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3336082T3 (da) | 2011-06-08 | 2020-04-27 | Translate Bio Inc | Spaltelige lipider |
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| CA2953265C (fr) * | 2014-07-02 | 2023-09-26 | Shire Human Genetic Therapies, Inc. | Encapsulation d'arn messager |
| AU2018224326B2 (en) * | 2017-02-27 | 2024-01-04 | Translate Bio, Inc. | Novel codon-optimized CFTR mRNA |
| WO2018170245A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin à large spectre contre le virus de la grippe |
| MA47787A (fr) | 2017-03-15 | 2020-01-22 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
| WO2018232357A1 (fr) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Formulations d'arn |
| WO2019046809A1 (fr) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Procédés de fabrication de nanoparticules lipidiques |
| KR102762217B1 (ko) * | 2017-10-20 | 2025-02-07 | 비온테크 에스이 | 치료법에 적합한 리포조말 rna 제형의 제조 및 저장 |
| WO2019104160A2 (fr) | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucléotides codant pour la phénylalanine hydroxylase pour le traitement de la phénylcétonurie |
| WO2019148101A1 (fr) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Vaccins à base d'arn contre le vrs |
| BR112020021054A2 (pt) | 2018-04-25 | 2021-02-17 | Ethris Gmbh | composição, processo para a preparação de uma composição, e, composições sólida e para uso |
| AU2019271132B2 (en) * | 2018-05-15 | 2026-02-05 | Translate Bio, Inc. | Subcutaneous delivery of messenger RNA |
| US11964051B2 (en) | 2018-05-16 | 2024-04-23 | Translate Bio, Inc. | Ribose cationic lipids |
| AU2019275068B2 (en) | 2018-05-24 | 2024-09-26 | Translate Bio, Inc. | Thioester cationic lipids |
| AU2019277361B2 (en) | 2018-05-30 | 2025-04-24 | Translate Bio, Inc. | Messenger RNA vaccines and uses thereof |
| US11547666B2 (en) | 2018-05-30 | 2023-01-10 | Translate Bio, Inc. | Cationic lipids comprising a steroidal moiety |
| WO2019232095A1 (fr) | 2018-05-30 | 2019-12-05 | Translate Bio, Inc. | Lipides cationiques vitaminiques |
| AU2019277355A1 (en) | 2018-05-30 | 2020-12-17 | Translate Bio, Inc. | Phosphoester cationic lipids |
| KR20210056331A (ko) | 2018-07-23 | 2021-05-18 | 트랜슬레이트 바이오 인코포레이티드 | 전령 rna의 건조 분말 제형 |
| ES2983019T3 (es) * | 2018-08-14 | 2024-10-21 | Ethris Gmbh | Formulaciones a base de lípidos que contienen sales para el suministro de ARN |
| IL280935B2 (en) * | 2018-08-24 | 2025-04-01 | Flagship Pioneering Innovations Vi Llc | Modified plant-based courier packaging and its uses |
| KR20210091120A (ko) | 2018-08-29 | 2021-07-21 | 트랜슬레이트 바이오 인코포레이티드 | Mrna-로딩된 지질 나노입자를 제조하는 개선된 공정 |
| US12564645B2 (en) | 2018-09-14 | 2026-03-03 | Translate Bio, Inc. | Methods for treatment of methylmalonic acidemia |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| WO2020061457A1 (fr) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Préparation de nanoparticules lipidiques et leurs méthodes d'administration |
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| KR20210090634A (ko) | 2018-10-19 | 2021-07-20 | 트랜슬레이트 바이오 인코포레이티드 | 전령 rna의 무펌프 캡슐화 |
| KR102860605B1 (ko) | 2018-11-09 | 2025-09-15 | 트랜슬레이트 바이오 인코포레이티드 | 에스테르, 티오에스테르, 이황화물, 및 무수물 모이어티가 삽입된 2,5-디옥소피페라진 |
| EP3876914A2 (fr) | 2018-11-09 | 2021-09-15 | Translate Bio, Inc. | Thérapie par l'arn messager pour le traitement des maladies oculaires |
| AU2019378763B2 (en) * | 2018-11-12 | 2025-06-26 | Translate Bio, Inc. | Methods for inducing immune tolerance |
| CN113412273B (zh) | 2019-01-07 | 2025-08-22 | 川斯勒佰尔公司 | 用于治疗原发性纤毛运动障碍的组合物和方法 |
| CA3123886A1 (fr) * | 2019-01-17 | 2020-07-23 | James DAHLMAN | Systemes d'administration de medicament contenant des cholesterols oxydes |
| MX2021009245A (es) * | 2019-01-31 | 2021-11-12 | Modernatx Inc | Metodos de preparacion de nanoparticulas lipidicas. |
| US20220177423A1 (en) | 2019-04-18 | 2022-06-09 | Translate Bio, Inc. | Cystine cationic lipids |
| ES2972014T3 (es) | 2019-04-22 | 2024-06-10 | Translate Bio Inc | Lípidos catiónicos de tioéster |
| US12453759B2 (en) | 2019-05-03 | 2025-10-28 | Translate Bio, Inc. | Di-thioester cationic lipids |
| EP3968952A1 (fr) * | 2019-05-14 | 2022-03-23 | Translate Bio, Inc. | Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnm |
| WO2020243540A1 (fr) | 2019-05-31 | 2020-12-03 | Translate Bio, Inc. | Lipides macrocycliques |
| AU2020297606B2 (en) | 2019-06-21 | 2026-04-02 | Translate Bio, Inc. | Tricine and citric acid lipids |
| WO2020257611A1 (fr) | 2019-06-21 | 2020-12-24 | Translate Bio, Inc. | Lipides cationiques comprenant une fraction hydroxy |
| ES2992127T3 (es) * | 2019-07-08 | 2024-12-09 | Translate Bio Inc | Nanopartículas lipídicas cargadas de ARNm mejoradas y sus procesos de fabricación |
| WO2021016430A1 (fr) | 2019-07-23 | 2021-01-28 | Translate Bio, Inc. | Compositions stables de nanoparticules lipidiques chargées en arnm et leurs procédés de fabrication |
| WO2021055609A1 (fr) | 2019-09-20 | 2021-03-25 | Translate Bio, Inc. | Arnm codant pour cftr modifiée |
| US12378560B2 (en) | 2019-10-29 | 2025-08-05 | Northwestern University | Sequence multiplicity within spherical nucleic acids |
| US12053551B2 (en) * | 2019-12-20 | 2024-08-06 | Translate Bio, Inc. | Process of preparing mRNA-loaded lipid nanoparticles |
| KR20220142432A (ko) | 2019-12-20 | 2022-10-21 | 트랜슬레이트 바이오 인코포레이티드 | 메신저 rna의 직장 전달 |
| WO2021142245A1 (fr) | 2020-01-10 | 2021-07-15 | Translate Bio, Inc. | Composés, compositions pharmaceutiques et méthodes pour moduler l'expression de la muc5b dans des cellules et des tissus pulmonaires |
| CN116133652A (zh) * | 2020-01-31 | 2023-05-16 | 摩登纳特斯有限公司 | 制备脂质纳米粒子的方法 |
| AU2021218671A1 (en) | 2020-02-10 | 2022-10-06 | Translate Bio, Inc. | Methods and compositions for messenger RNA purification |
| MX2022010117A (es) | 2020-02-18 | 2022-11-14 | Translate Bio Inc | Procesos mejorados para la transcripción in vitro del arn mensajero. |
| WO2021173840A1 (fr) | 2020-02-25 | 2021-09-02 | Translate Bio, Inc. | Procédés améliorés de préparation de nanoparticules lipidiques chargées d'arnm |
| CN115667207B (zh) | 2020-04-01 | 2025-09-16 | 翻译生物公司 | 基于酚酸脂质的阳离子脂质 |
| EP4146680A1 (fr) | 2020-05-07 | 2023-03-15 | Translate Bio, Inc. | Composition et méthodes de traitement d'une dyskinésie ciliaire primitive |
| WO2021226436A1 (fr) | 2020-05-07 | 2021-11-11 | Translate Bio, Inc. | Séquences nucléotidiques optimisées codant pour des antigènes du sras-cov-2 |
| US12605399B2 (en) | 2020-05-07 | 2026-04-21 | Translate Bio, Inc. | Compositions for CFTR MRNA therapy |
| US12514932B2 (en) | 2020-05-14 | 2026-01-06 | Translate Bio, Inc. | PEG lipidoid compounds |
| EP4149425A1 (fr) | 2020-05-15 | 2023-03-22 | Translate Bio, Inc. | Formulations de nanoparticules lipidiques pour l'administration d'arnm |
| TW202220637A (zh) * | 2020-08-06 | 2022-06-01 | 美商現代公司 | 製備脂質奈米顆粒之方法 |
| EP4216933B1 (fr) | 2020-09-23 | 2024-09-18 | Translate Bio, Inc. | Lipides cationiques à base de pipérazine |
| KR20230092914A (ko) | 2020-09-23 | 2023-06-26 | 트랜슬레이트 바이오 인코포레이티드 | Tes계 양이온성 지질 |
| US20220110884A1 (en) | 2020-10-12 | 2022-04-14 | Translate Bio, Inc. | Process of preparing mrna-loaded lipid nanoparticles |
| US20220133631A1 (en) | 2020-10-12 | 2022-05-05 | Translate Bio, Inc. | Process of preparing ice-based lipid nanoparticles |
| KR20230118715A (ko) * | 2020-10-14 | 2023-08-11 | 조지 메이슨 리서치 파운데이션 인코포레이티드 | 이온화 가능 지질 및 이의 제조 및 사용 방법 |
| US11771652B2 (en) | 2020-11-06 | 2023-10-03 | Sanofi | Lipid nanoparticles for delivering mRNA vaccines |
| AU2021373892A1 (en) | 2020-11-09 | 2023-07-06 | Translate Bio, Inc. | Improved compositions for delivery of codon-optimized mrna |
| WO2022204549A1 (fr) | 2021-03-25 | 2022-09-29 | Translate Bio, Inc. | Séquences nucléotidiques optimisées codant pour le domaine extracellulaire de la protéine ace2 humaine ou une portion de celle-ci |
| WO2022225918A1 (fr) | 2021-04-19 | 2022-10-27 | Translate Bio, Inc. | Compositions améliorées pour l'administration d'arnm |
| WO2022264109A1 (fr) | 2021-06-18 | 2022-12-22 | Sanofi | Vaccins multivalents contre la grippe |
| JP2024527541A (ja) | 2021-07-01 | 2024-07-25 | トランスレイト バイオ， インコーポレイテッド | Ｍｒｎａの送達のための組成物 |
| TW202320737A (zh) * | 2021-07-26 | 2023-06-01 | 美商現代公司 | 製備用於將酬載分子遞送至氣道上皮之脂質奈米粒子組成物之製程 |
| IL309505A (en) | 2021-09-03 | 2024-02-01 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| US20250027108A1 (en) | 2021-10-29 | 2025-01-23 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| TW202346593A (zh) | 2021-11-05 | 2023-12-01 | 法商賽諾菲公司 | 呼吸道融合病毒rna疫苗 |
| AU2022388747A1 (en) | 2021-11-10 | 2024-06-20 | Translate Bio, Inc. | Composition and methods for treatment of primary ciliary dyskinesia |
| CA3239417A1 (fr) | 2021-11-30 | 2023-06-08 | Yvonne CHAN | Vaccins contre le metapneumovirus humain |
| CN119095613A (zh) | 2021-12-17 | 2024-12-06 | 赛诺菲 | 莱姆病rna疫苗 |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| JP2025509507A (ja) | 2022-03-16 | 2025-04-11 | トランスレイト バイオ， インコーポレイテッド | 非対称ピペラジン系カチオン性脂質 |
| JP2025512049A (ja) | 2022-04-13 | 2025-04-16 | サノフイ | 「ｇｏｏｄ」緩衝液ベースのカチオン性脂質 |
| CN119522105A (zh) | 2022-05-06 | 2025-02-25 | 赛诺菲 | 核酸疫苗的信号序列 |
| CA3248209A1 (fr) | 2022-05-25 | 2023-11-30 | CureVac SE | Vaccin à base d’acide nucléique codant pour un polypeptide antigénique fimh d’escherichia coli |
| WO2023231959A2 (fr) | 2022-05-30 | 2023-12-07 | Shanghai Circode Biomed Co., Ltd | Compositions d'arn circulaire synthétiques et leurs procédés d'utilisation |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| WO2024028492A1 (fr) | 2022-08-04 | 2024-02-08 | Sanofi | Évaluation quantitative d'encapsulation d'arn |
| EP4577236A1 (fr) | 2022-08-22 | 2025-07-02 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Vaccins contre les coronavirus |
| EP4608442A1 (fr) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Vaccin à base d'acide nucléique |
| AU2023374764A1 (en) | 2022-11-04 | 2025-06-19 | Sanofi Pasteur Inc. | Respiratory syncytial virus rna vaccination |
| WO2024102677A1 (fr) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Compositions d'arn circulaire |
| WO2024126809A1 (fr) | 2022-12-15 | 2024-06-20 | Sanofi | Arnm codant pour une particule de type virus de la grippe |
| EP4637813A1 (fr) | 2022-12-20 | 2025-10-29 | Sanofi Pasteur | Vaccin contre l'arnm de rhinovirus |
| WO2024160826A1 (fr) | 2023-01-31 | 2024-08-08 | BioNTech SE | Compositions et procédés |
| JP2026504797A (ja) | 2023-03-02 | 2026-02-10 | サノフィ・パスツール | クラミジア（Ｃｈｌａｍｙｄｉａ）の治療に使用するための組成物 |
| JP2026509258A (ja) | 2023-03-08 | 2026-03-17 | キュアバック エスイー | 核酸送達のための新規な脂質ナノ粒子製剤 |
| WO2024231727A1 (fr) | 2023-05-05 | 2024-11-14 | Sanofi | Compositions destinées à être utilisées dans le traitement de l'acné |
| TW202508620A (zh) | 2023-05-10 | 2025-03-01 | 尼可拉斯 克拉克 | 呼吸道mrna組合疫苗 |
| WO2024230934A1 (fr) | 2023-05-11 | 2024-11-14 | CureVac SE | Acide nucléique thérapeutique pour le traitement de maladies ophtalmiques |
| MX2025015001A (es) | 2023-06-12 | 2026-02-03 | Sanofi Sa | Lipidos cationicos basados en tricina y acido citrico |
| EP4724456A1 (fr) | 2023-06-12 | 2026-04-15 | Sanofi | Lipides cationiques à base de stérol avec des groupes de tête aromatiques |
| CN121568920A (zh) | 2023-06-12 | 2026-02-24 | 赛诺菲 | 具有芳香族头基团的基于三(羟甲基)甲基甘氨酸和柠檬酸的阳离子脂质 |
| EP4734960A1 (fr) | 2023-06-28 | 2026-05-06 | Sanofi Pasteur Inc. | Analogues de stérol dans des formulations de nanoparticules lipidiques |
| KR20260040011A (ko) | 2023-06-28 | 2026-03-23 | 사노피 백신즈 유에스 인크. | 핵산 전달을 위한 헬퍼 지질 |
| EP4735450A1 (fr) | 2023-06-28 | 2026-05-06 | Sanofi Pasteur, Inc. | Lipides ionisables à base de dianhydrohexitol pour la délivrance d'acides nucléiques |
| CN121889496A (zh) | 2023-07-19 | 2026-04-17 | 赛诺菲 | 牙龈卟啉单胞菌抗原构建体 |
| WO2025051975A1 (fr) | 2023-09-06 | 2025-03-13 | Sanofi | Polypeptides d'hémagglutinine de la grippe b modifiés et acides nucléiques et leurs utilisations |
| WO2025061967A1 (fr) | 2023-09-20 | 2025-03-27 | Sanofi | Lipides cationiques à base de tampons de good pour la délivrance d'acides nucléiques |
| US12599560B2 (en) | 2023-11-02 | 2026-04-14 | Longuide Biopharma Corporation | Lipids and lipid nanoparticle formulations |
| CN121219273A (zh) * | 2023-11-02 | 2025-12-26 | 深圳厚存纳米药业有限公司 | 脂质和脂质纳米颗粒制剂 |
| WO2025101862A1 (fr) | 2023-11-08 | 2025-05-15 | Axelyf ehf. | Liants d'anticorps à domaine unique de myc |
| WO2025104351A1 (fr) | 2023-11-17 | 2025-05-22 | Sanofi Pasteur Inc. | Dosages par clhp pour détecter de multiples constructions d'arnm |
| WO2025117969A1 (fr) | 2023-12-01 | 2025-06-05 | Orna Therapeutics, Inc. | Procédé de fabrication de nanoparticules lipidiques |
| WO2025134071A1 (fr) | 2023-12-22 | 2025-06-26 | Sanofi | Lipides ionisables à base d'acide malique et d'acide glutarique |
| WO2025141521A1 (fr) | 2023-12-29 | 2025-07-03 | Sanofi | Lipides comportant des fractions dendritiques |
| WO2025166238A1 (fr) | 2024-01-31 | 2025-08-07 | Orna Therapeutics, Inc. | Lipides de polyéthylène glycol à détachement rapide |
| WO2025196065A1 (fr) | 2024-03-20 | 2025-09-25 | Sanofi | Nouveaux lipides à base d'homocystéine et leur utilisation pour l'administration d'acides nucléiques |
| WO2025210592A1 (fr) | 2024-04-05 | 2025-10-09 | Sanofi Pasteur Inc. | Dosages de contrôle de qualité de lnp-arnm de cellules musculaires |
| WO2025261607A1 (fr) | 2024-06-21 | 2025-12-26 | BioNTech SE | Particules, compositions et procédés |
| WO2026006524A2 (fr) | 2024-06-26 | 2026-01-02 | Sanofi Pasteur Inc. | Lipides cationiques de bis-ester et d'amide |
| WO2026003373A1 (fr) | 2024-06-28 | 2026-01-02 | Sanofi | Lipides cationiques à base de lipide d'acide phénolique |
| WO2026008743A1 (fr) | 2024-07-02 | 2026-01-08 | Sanofi Pasteur Inc. | Polymère polyanionique soluble dans l'eau en tant qu'adjuvant pour acide nucléique formulé par un support |
| WO2026027730A1 (fr) | 2024-07-31 | 2026-02-05 | Sanofi | Polypeptides d'hémagglutinine de la grippe h5 modifiés et acides nucléiques et leurs utilisations |
| WO2026033123A1 (fr) | 2024-08-08 | 2026-02-12 | Sanofi Pasteur Inc. | Formulations de nanoparticules lipidiques pour l'administration d'arnm |
| WO2026053147A1 (fr) | 2024-09-05 | 2026-03-12 | Sanofi Pasteur Inc. | Lipides auxiliaires et compositions de lnp les comprenant |
| WO2026052773A1 (fr) | 2024-09-06 | 2026-03-12 | Sanofi | Polypeptides d'hémagglutinine de la grippe a modifiés et acides nucléiques et leurs utilisations |
| WO2026094020A1 (fr) | 2024-11-04 | 2026-05-07 | Sanofi Pasteur Inc. | Lipides cationiques à base d'acide phtalique et d'acide vanillique |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4857319A (en) * | 1985-01-11 | 1989-08-15 | The Regents Of The University Of California | Method for preserving liposomes |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5049392A (en) * | 1989-01-18 | 1991-09-17 | The Liposome Company, Inc. | Osmotically dependent vesicles |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| JP2599492B2 (ja) * | 1990-08-21 | 1997-04-09 | 第一製薬株式会社 | リポソーム製剤の製造法 |
| ATE132742T1 (de) * | 1991-08-16 | 1996-01-15 | Vical Inc | Zusammensetzung und verfahren zur behandlung von zystischer fibrose |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| US6897200B1 (en) * | 1998-10-14 | 2005-05-24 | University Of Kentucky Research Foundation | Oligonucleotide delivery systems for camptothecins |
| ATE397488T1 (de) * | 1998-11-13 | 2008-06-15 | Heriot William A | Vorrichtung zur herstellung von liposomen |
| ES2235916T3 (es) * | 1999-07-15 | 2005-07-16 | Inex Pharmaceuticals Corp. | Preparacion de agentes terapeuticos de encapsulacion lipidica. |
| US7094423B1 (en) * | 1999-07-15 | 2006-08-22 | Inex Pharmaceuticals Corp. | Methods for preparation of lipid-encapsulated therapeutic agents |
| AU6105300A (en) * | 1999-07-16 | 2001-02-05 | Purdue Research Foundation | Vinyl ether lipids with cleavable hydrophilic headgroups |
| ATE536418T1 (de) | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | Lipidverkapselte interferenz-rna |
| JP5777519B2 (ja) | 2008-10-09 | 2015-09-09 | テクミラ ファーマシューティカルズ コーポレイション | 改良されたアミノ脂質および核酸の送達方法 |
| MX2011004859A (es) | 2008-11-07 | 2011-08-03 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
| PL3338765T3 (pl) | 2009-12-01 | 2019-06-28 | Translate Bio, Inc. | Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych |
| CN102018672B (zh) * | 2010-11-29 | 2013-09-18 | 广州朗圣药业有限公司 | 一种水溶性药物的脂质体冻干组合物及其制备方法 |
| DK3336082T3 (da) * | 2011-06-08 | 2020-04-27 | Translate Bio Inc | Spaltelige lipider |
| PT2717893T (pt) * | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
| KR20150000461A (ko) | 2011-10-27 | 2015-01-02 | 메사추세츠 인스티튜트 오브 테크놀로지 | 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체 |
| WO2013086526A1 (fr) * | 2011-12-09 | 2013-06-13 | The Regents Of The University Of California | Encapsulation liposomale de médicaments |
| WO2013143555A1 (fr) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Formulation d'arn pour immunothérapie |
| US10258698B2 (en) * | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| TW201534578A (zh) * | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
| CA2928040A1 (fr) * | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Administration d'arnm au snc et utilisations associees |
| EP3110954A1 (fr) * | 2014-02-26 | 2017-01-04 | Ethris GmbH | Compositions pour une administration gastro-intestinale d'arn |
| US10022455B2 (en) | 2014-05-30 | 2018-07-17 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
| CA2953265C (fr) | 2014-07-02 | 2023-09-26 | Shire Human Genetic Therapies, Inc. | Encapsulation d'arn messager |
| WO2016118724A1 (fr) | 2015-01-21 | 2016-07-28 | Moderna Therapeutics, Inc. | Compositions de nanoparticules lipidiques |
| EP3247398A4 (fr) | 2015-01-23 | 2018-09-26 | Moderna Therapeutics, Inc. | Compositions de nanoparticules lipidiques |
| JP7114465B2 (ja) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | 薬剤の細胞内送達のための化合物および組成物 |
| US20190167811A1 (en) | 2016-04-13 | 2019-06-06 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
-
2017
- 2017-11-10 MA MA046762A patent/MA46762A/fr unknown
- 2017-11-10 EP EP17818338.0A patent/EP3538073A1/fr active Pending
- 2017-11-10 WO PCT/US2017/061113 patent/WO2018089801A1/fr not_active Ceased
- 2017-11-10 JP JP2019524194A patent/JP7738979B2/ja active Active
- 2017-11-10 US US15/809,680 patent/US20180153822A1/en not_active Abandoned
- 2017-11-10 AU AU2017357758A patent/AU2017357758B2/en active Active
- 2017-11-10 CA CA3041345A patent/CA3041345A1/fr active Pending
-
2023
- 2023-06-02 US US18/328,206 patent/US20240041789A1/en active Pending
- 2023-08-31 JP JP2023141009A patent/JP2023166489A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7738979B2 (ja) | 2025-09-16 |
| WO2018089801A1 (fr) | 2018-05-17 |
| JP2019533707A (ja) | 2019-11-21 |
| EP3538073A1 (fr) | 2019-09-18 |
| JP2023166489A (ja) | 2023-11-21 |
| CA3041345A1 (fr) | 2018-05-17 |
| AU2017357758B2 (en) | 2023-11-16 |
| US20240041789A1 (en) | 2024-02-08 |
| AU2017357758A1 (en) | 2019-05-16 |
| US20180153822A1 (en) | 2018-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3652186A4 (fr) | Procédé général et direct pour préparer des nanoparticules à structure organométallique fonctionnalisées par des oligonucléotides | |
| EP3525806A4 (fr) | Procédé de lyophilisation d'exosomes | |
| EP3331896A4 (fr) | Procédés de préparation d'acides biliaires et de leurs dérivés | |
| EP2841486A4 (fr) | Nanoparticules polymères et leur procédé de préparation | |
| MA52906A (fr) | Procédé de préparation d'amg 416 | |
| EP3378869A4 (fr) | Procédé de production d'oligonucléotide | |
| MA71469A (fr) | Procédé de préparation d'oligomères morpholino de phosphorodiamidate | |
| EP3006445A4 (fr) | Hydrogénosulfate d'inhibiteur de janus kinase (jak) et son procédé de préparation | |
| LT3636764T (lt) | 3`utr sekos, skirtos rnr stabilizavimui | |
| EP3383436A4 (fr) | Procédé amélioré de préparation de vert d'indocyanine | |
| EP3398957A4 (fr) | Procédé de synthèse de l'ételcalcétide | |
| EP3381498A4 (fr) | Microaiguille et procédé pour la produire | |
| EP3398958A4 (fr) | Polyamino-acide, conjugué protéine-polyamino-acide et procédé de préparation correspondant | |
| EP2957576A4 (fr) | Procédé de préparation d'une résine superabsorbante | |
| EP3341359A4 (fr) | Procédé de préparation d'aprémilast | |
| EP2977448A4 (fr) | Procédé de préparation de chondrocytes | |
| EP2900084A4 (fr) | Procédé de préparation d'arôme naturel de b uf | |
| EP3766869A4 (fr) | Procédé simple de préparation d'avibactam | |
| EP3334777A4 (fr) | Procédé de revêtement d'articles | |
| EP3296282A4 (fr) | Procédé de production d'hydrohalofluorooléfines | |
| MA42423A (fr) | Procédé de préparation d'un revêtement | |
| EP3015479A4 (fr) | Procédé de préparation d'une résine superabsorbante | |
| EP3363466A4 (fr) | Procédé de préparation d'agent de contraste pour imagerie par résonance magnétique | |
| EP3388424A4 (fr) | Procédé de préparation de médicaments lcz696 contre l'insuffisance cardiaque | |
| EP3513888A4 (fr) | Procédé de coulée continue |